Additionally, this study aimed to describe utilisation of the first SGLT-2 inhibitor approved for CKD treatment, dapagliflozin, and renin-angiotensin system [RAS] inhibitors following new initiation with these kidney-protective treatments. This evidence concerns the gene SLC5A2 and chronic kidney disease.